SOMAVAC Medical Solutions is a technology company.
SOMAVAC Medical Solutions has raised $3.5M across 3 funding rounds.
SOMAVAC Medical Solutions has raised $3.5M in total across 3 funding rounds.
SOMAVAC Medical Solutions has raised $3.5M in total across 3 funding rounds.
SOMAVAC Medical Solutions's investors include Innova Memphis.
SOMAVAC Medical Solutions is a Memphis-based medical device company developing the SOMAVAC® system, an FDA-cleared smart surgical drain pump that applies continuous negative pressure to prevent seromas and manage post-surgical fluids.[1][3][4][6] It targets patients undergoing plastic and general surgeries like mastectomies, breast reconstructions, hernia repairs, tummy tucks, and orthopedic procedures, solving the mess, discomfort, and complications of traditional bulb drains by enabling faster recovery, drains removed 30% sooner, and a discreet, wearable design.[1][2][4][6] With under 25 employees and revenue below $5 million, the company shows growth momentum through expanded manufacturing, patents, and strong reception at events like the ASPS Annual Meeting.[1][2][3]
SOMAVAC was co-founded by Esra Roan (CEO at the time of early milestones) and Joshua Herwig, who developed the idea for a battery-powered "smart" pump to replace cumbersome Jackson-Pratt bulbs, drawing from Memphis's medical device innovation history.[3] In early August 2021, they secured US Patent 11,078,898 for the continuous negative-pressure device, which is as compact as an iPhone and sensor-driven to maintain steady pressure like a thermostat.[1][3] Pivotal moments include FDA clearance for the SOMAVAC® SVS as the only smart pump for seroma prevention in plastic and general surgery, scaling to a 5,000-square-foot facility in Bartlett by September 2021, and leadership transition to CEO Elizabeth Hoff, who has driven presentations at LSI Europe and emphasis on breast cancer recovery.[1][3][5][6] Early traction built on addressing "the most ignored known problem" of seromas in large flap surgeries.[1]
SOMAVAC rides the trend of patient-centric medtech innovation, shifting post-surgical care from suboptimal, messy drains to automated, wearable negative pressure wound therapy amid rising breast cancer surgeries and reconstructive procedures.[1][2][4] Timing aligns with FDA clearances (e.g., SOMAVAC® 100 in 2022, building on 2018 predicate) and post-pandemic emphasis on homecare to reduce hospital stays and complications like seromas, which affect recovery in flap surgeries.[1][6] Market forces favoring it include Memphis's med device hub status, patent protection, and demand for mess-free solutions that cut complications—evidenced by enthusiastic ASPS and LSI responses—positioning SOMAVAC to influence plastic surgery standards by humanizing recovery.[1][3]
SOMAVAC is poised for scaled adoption in breast reconstruction and beyond, leveraging manufacturing ramp-up, clinical hires, and CEO Hoff's advocacy to capture share in the $multi-billion wound care market.[1][2][3] Trends like AI-enhanced med devices and value-based care will amplify its sensor-driven edge, potentially expanding indications or global reach. Its influence may evolve from niche disruptor to protocol-changer, redefining post-op recovery from "unbearable" bulbs to "wearable" ease—echoing its core promise of faster healing without compromise.[4]
SOMAVAC Medical Solutions has raised $3.5M across 3 funding rounds. Most recently, it raised $3.0M Seed in October 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2019 | $3.0M Seed | Innova Memphis | |
| Oct 1, 2018 | $500K Seed | Innova Memphis | |
| May 1, 2016 | $25K Seed | Innova Memphis |